8-K

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
     PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

                                 Date of Report
                       (Date of earliest event reported):

                                November 24, 2003



                                 ANTIGENICS INC.
             (Exact name of registrant as specified in its charter)

                DELAWARE           000-29089                    06-1562417

 (State or other jurisdiction of (Commission file number)     (I.R.S. Employer
  incorporation of organization)                             Identification No.)

                          630 FIFTH AVENUE, SUITE 2100
                            NEW YORK, NEW YORK 10111
              (Address of principal executive offices and zip code)

                                 (212) 994-8200
              (Registrant's telephone number, including area code)













Item 5.  Other Events

      On November 24, 2003, the Company announced that the US Food and Drug
Administration (FDA) has lifted the partial clinical hold on the two Phase III
clinical trials of the company's personalized cancer vaccine Oncophage(R)
(HSPPC-96). The full text of the press release issued in connection with the
announcement is attached as Exhibit 99.1 to this current report on Form 8-K.

Item 7.  Financial Statements and Exhibits.

               (c) Exhibits:

                      99.1     Press Release dated November 24, 2003













                                   SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                           ANTIGENICS INC.

Date: November 24, 2003                   By: /s/ Garo H. Armen
                                              -----------------
                                            Garo H. Armen, Ph.D.
                            Chairman and Chief Executive Officer













                                  EXHIBIT INDEX


         The following designated exhibits are filed herewith:

         Exhibits:

         99.1                       Press Release dated November 24, 2003

EX-99

                                                                   Exhibit 99.1

FDA Lifts Clinical Hold on Antigenics' Phase III Trials Of Oncophage;
Patient Enrollment Allowed to Resume Immediately

    NEW YORK--(BUSINESS WIRE)--Nov. 24, 2003--Antigenics Inc. (NASDAQ:
AGEN) announced today that the US Food and Drug Administration (FDA)
has lifted the partial clinical hold on the two Phase III clinical
trials of the company's personalized cancer vaccine Oncophage(R)
(HSPPC-96). The agency's decision to lift the hold comes 13 weeks
after its request for product characterization information in
September 2003.
    Antigenics will immediately resume patient enrollment in its Phase
III trials of Oncophage.
    "Our team worked hard to provide the information within our
targeted timelines," said Garo H. Armen, PhD, chairman and CEO of
Antigenics. "We are grateful for the FDA's rapid and thorough review
of our submission."
    The FDA had placed two Antigenics studies on partial clinical hold
to review product characterization data. All other Oncophage trials,
including Phase I and II studies, were unaffected by the hold.
    Antigenics is working to develop personalized immunotherapeutics
and revolutionary treatments for cancers, infectious diseases and
autoimmune disorders.

    This press release contains forward-looking statements, including
statements regarding resuming patient enrollment for Antigenics' Phase
III trials of Oncophage. These statements are subject to risks and
uncertainties that could cause actual results to differ materially to
those projected in these forward-looking statements. These risks and
uncertainties include, among other factors, any negative impact the
partial clinical hold may have had on the willingness of physicians
and patients to participate in the trials, any further regulatory
actions that delay the trials, and the factors related to the
regulatory approval process described in the company's periodic
filings with the Securities and Exchange Commission. Please see the
"Factors That May Impact Future Results" section of the Management's
Discussion and Analysis of Financial Condition and Results of
Operations in the Antigenics Quarterly Report on Form 10-Q for the
quarter ended September 30, 2003, for a full discussion of these and
other risk factors. Antigenics cautions investors not to place
significant reliance on the forward-looking statements contained in
this press release. These statements speak only as of the date of this
document, and Antigenics undertakes no obligation to update or revise
the statements. All forward-looking statements are expressly qualified
in their entirety by this cautionary statement.

    CONTACT: Antigenics Inc., New York
             Corporate Communications:
             Sunny Uberoi, 212-994-8206
             suberoi@antigenics.com
              or
             Investor Relations:
             Tanya Sripanich, 212-994-8244
             tsripanich@antigenics.com